Categories: Clinical TrialDNANews

Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark. The presentation will highlight new data from the Company’s emerging preclinical program for herpes simplex virus-1 keratitis (HSV-1 Keratitis).

Presentation details:

Title: CRISPR/Cas9-mediated gene editing delivered by a single AAV vector inhibits viral reactivation of HSV-1 in a latent rabbit keratitis model
Session Title: Pre-clinical/Clinical Trials II
Abstract: 81
Presenter: Kevin Luk, Excision BioTherapeutics
Location: Ballroom 3
Date/Time: April 24, 2024, 16:45 to 18:25 pm (CEST)

About Excision BioTherapeutics, Inc.

Excision BioTherapeutics, Inc. develops CRISPR-based medicines as potential cures for serious latent viral infectious diseases based on its proprietary multiplexed gene editing platform that unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies. The Company’s pipeline targets large, underserved markets including herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Excision’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. For more information, please visit www.excision.bio.

Contact:
John Fraunces
LifeSci Advisors
917-355-2395
jfraunces@lifesciadvisors.com

Staff

Recent Posts

Best Steroids For Bodybuilding (Muscle Growth & Bulking) From CrazyBulk in 2025

NEW YORK, March 22, 2025 (GLOBE NEWSWIRE) -- “CrazyBulk Stacks. Want the best results? Then…

13 hours ago

Financière de Tubize – Annual report 2024

Annual Report 2024Regulated information 22 March 2025 The board of directors of Financière de Tubize…

13 hours ago

Prime Biome Reviews 2025 (Investigative Report) Ingredients, Benefits, Complaints, And Honest Consumer Report!

ST. PETERSBURG, Fla., March 22, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a probiotic for…

13 hours ago

Arialief Reviews (Is It Safe And Legit To Use?) What Do Arialief Consumer Reports Say About Its Efficacy?

AURORA, Colo., March 22, 2025 (GLOBE NEWSWIRE) -- Arialief is a unique nerve pain and…

13 hours ago

ProDentim Reviews (2025) Is This Probiotic Formula Really A Game-Changer For Teeth And Gum Health?

TALLMADGE, Ohio, March 22, 2025 (GLOBE NEWSWIRE) -- qProDentim is designed to improve oral health…

13 hours ago

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the…

13 hours ago